Business Description
Faron Pharmaceuticals Oy
ISIN : FI4000153309
Description
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested for the prevention of complications that arise from cytokine release syndrome, or hyperinflammatory conditions.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.79 | |||||
| Equity-to-Asset | -0.78 | |||||
| Debt-to-Equity | -1.24 | |||||
| Debt-to-EBITDA | -0.55 | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 10.9 | |||||
| 3-Year EPS without NRI Growth Rate | 9.7 | |||||
| 3-Year FCF Growth Rate | 11.8 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.31 | |||||
| 9-Day RSI | 49.04 | |||||
| 14-Day RSI | 46.75 | |||||
| 3-1 Month Momentum % | 12.33 | |||||
| 6-1 Month Momentum % | 16.67 | |||||
| 12-1 Month Momentum % | 145.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.09 | |||||
| Quick Ratio | 1.09 | |||||
| Cash Ratio | 0.93 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.8 | |||||
| Shareholder Yield % | -11.41 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -132.53 | |||||
| ROIC % | -256.64 | |||||
| 3-Year ROIIC % | 619.02 | |||||
| ROC (Joel Greenblatt) % | -7688.7 | |||||
| ROCE % | -693.96 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -12.9 | |||||
| EV-to-Forward-EBIT | -3.73 | |||||
| EV-to-EBITDA | -13.09 | |||||
| EV-to-Forward-EBITDA | -9.84 | |||||
| EV-to-Forward-Revenue | 768.72 | |||||
| EV-to-FCF | -11.59 | |||||
| Earnings Yield (Greenblatt) % | -7.74 | |||||
| FCF Yield % | -8.25 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers